Editorial: Immune dysfunction in nephrotic syndrome - recent advances and new roads ahead

COPYRIGHT © 2022 Seitz-Polski, Audard, Ghiggeri and Tomas. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. TYPE Editorial PUBLISHED 02 August 2022 DOI 10.3389/fimmu.2022.985925

[1]  E. Fiaccadori,et al.  Case Report: Atypical Manifestations Associated With FOXP3 Mutations. The “Fil Rouge” of Treg Between IPEX Features and Other Clinical Entities? , 2022, Frontiers in Immunology.

[2]  S. Waikar,et al.  Discovery of Autoantibodies Targeting Nephrin in Minimal Change Disease Supports a Novel Autoimmune Etiology , 2021, Journal of the American Society of Nephrology : JASN.

[3]  N. Bec,et al.  Contactin-1 is a novel target antigen in membranous nephropathy associated with chronic inflammatory demyelinating polyneuropathy. , 2021, Kidney international.

[4]  M. Prunotto,et al.  Human or Chimeric Monoclonal Anti-CD20 Antibodies for Children with Nephrotic Syndrome: A Superiority Randomized Trial , 2021, Journal of the American Society of Nephrology : JASN.

[5]  Fei Liu,et al.  The important roles and molecular mechanisms of annexin A2 autoantibody in children with nephrotic syndrome , 2021, Annals of translational medicine.

[6]  Aaron J. Storey,et al.  Transforming Growth Factor Beta Receptor 3 (TGFBR3)–Associated Membranous Nephropathy , 2021, Kidney360.

[7]  Aaron J. Storey,et al.  Serine Protease HTRA1 as a Novel Target Antigen in Primary Membranous Nephropathy , 2021, Journal of the American Society of Nephrology : JASN.

[8]  Sidhartha Chaudhry,et al.  Protocadherin 7–Associated Membranous Nephropathy , 2020, Journal of the American Society of Nephrology : JASN.

[9]  J. Grande,et al.  In Patients with Membranous Lupus Nephritis, Exostosin-Positivity and Exostosin-Negativity Represent Two Different Phenotypes. , 2021, Journal of the American Society of Nephrology : JASN.

[10]  Aaron J. Storey,et al.  Neural cell adhesion molecule 1 is a novel autoantigen in membranous lupus nephritis. , 2020, Kidney international.

[11]  Aaron J. Storey,et al.  NELL1 is a target antigen in malignancy-associated membranous nephropathy. , 2020, Kidney international.

[12]  F. Emma,et al.  Semaphorin 3B-associated membranous nephropathy is a distinct type of disease predominantly present in pediatric patients. , 2020, Kidney international.

[13]  Yan Zhang,et al.  IL-17 aggravates renal injury by promoting podocyte injury in children with primary nephrotic syndrome , 2020, Experimental and therapeutic medicine.

[14]  P. Ravani,et al.  Low-dose ofatumumab for multidrug-resistant nephrotic syndrome in children: a randomized placebo-controlled trial , 2020, Pediatric Nephrology.

[15]  M. Jadoul,et al.  Neural epidermal growth factor-like 1 protein (NELL-1) associated membranous nephropathy. , 2020, Kidney international.

[16]  E. Daugas,et al.  Autoantibodies against podocytic UCHL1 are associated with idiopathic nephrotic syndrome relapses and induce proteinuria in mice. , 2018, Journal of autoimmunity.

[17]  D. Sahali,et al.  NEPHRUTIX: A randomized, double-blind, placebo vs Rituximab-controlled trial assessing T-cell subset changes in Minimal Change Nephrotic Syndrome. , 2017, Journal of autoimmunity.

[18]  L. Ravà,et al.  B Cell Reconstitution after Rituximab Treatment in Idiopathic Nephrotic Syndrome. , 2016, Journal of the American Society of Nephrology : JASN.

[19]  P. Ravani,et al.  Anti-CD20 Antibodies for Idiopathic Nephrotic Syndrome in Children. , 2016, Clinical journal of the American Society of Nephrology : CJASN.

[20]  P. Ravani,et al.  A Pilot Study of IL2 in Drug-Resistant Idiopathic Nephrotic Syndrome , 2015, PloS one.

[21]  Philip D. Hodgkin,et al.  The generation of antibody-secreting plasma cells , 2015, Nature Reviews Immunology.

[22]  J. Klein,et al.  Thrombospondin type-1 domain-containing 7A in idiopathic membranous nephropathy. , 2015, The New England journal of medicine.

[23]  C. Copie-Bergman,et al.  Minimal Change Nephrotic Syndrome Associated With Non-Hodgkin Lymphoid Disorders , 2014, Medicine.

[24]  B. Basu.  Ofatumumab for rituximab-resistant nephrotic syndrome. , 2014, The New England journal of medicine.

[25]  D. Sahali,et al.  Immunopathogenesis of idiopathic nephrotic syndrome with relapse , 2014, Seminars in Immunopathology.

[26]  克治 桑門.  海外論文紹介 : M-Type Phospholipase A2 Receptor as Target Antigen in Idiopathic Membranous Nephropathy , 2010 .

[27]  David M. Beck,et al.  M-type phospholipase A2 receptor as target antigen in idiopathic membranous nephropathy. , 2009, The New England journal of medicine.

[28]  H. Kanegane,et al.  Minimal change nephrotic syndrome associated with immune dysregulation, polyendocrinopathy, enteropathy, X-linked syndrome , 2009, Pediatric Nephrology.

[29]  Chul-Park,et al.  A Retrospective Study in 18 Cases , 2006 .

[30]  Emile de Heer,et al.  Role of truncating mutations in MME gene in fetomaternal alloimmunisation and antenatal glomerulopathies , 2004, The Lancet.

[31]  Abdulmajeed Al Abdukareem.  Randomized, placebo-controlled trial , 2004, Annals of Saudi medicine.

[32]  G. Tirino,et al.  T-lymphocyte populations and cytokines in childhood nephrotic syndrome. , 2002, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[33]  S. Jordan,et al.  Th1 and Th2 cytokine mRNA profiles in childhood nephrotic syndrome: evidence for increased IL-13 mRNA expression in relapse. , 1999, Journal of the American Society of Nephrology : JASN.

[34]  A. Koyama,et al.  A glomerular permeability factor produced by human T cell hybridomas. , 1991, Kidney international.

[35]  R. Shalhoub.  Pathogenesis of lipoid nephrosis: a disorder of T-cell function. , 1974, Lancet.